ArticleBreast cancer research and treatment2016

Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.

Xiao-Long Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.